초록 ▼

A composition includes particles including at least about 95 wt % of amphotericin B, wherein the particles have a mass median diameter ranging from about 1.1 μm to about 1.9 μm. Another composition also includes particles including at least about 95 wt % of amphotericin B, wherein at least

A composition includes particles including at least about 95 wt % of amphotericin B, wherein the particles have a mass median diameter ranging from about 1.1 μm to about 1.9 μm. Another composition also includes particles including at least about 95 wt % of amphotericin B, wherein at least about 80 wt % of the particles have a geometric diameter ranging from about 1.1 μm to about 1.9 μm. Yet another composition includes particles including amphotericin B, wherein the particles have a mass median diameter less than about 1.9 μm, and wherein the amphotericin B has a crystallinity level of at least about 20%. Unit dosage forms, delivery systems, and methods may involve similar compositions.

대표청구항 ▼

What is claimed is: 1. A composition, for localized delivery to the lungs as a powder, the composition consisting essentially of: particles comprising at least about 95 wt % of amphotericin B, wherein the particles comprise a crystallinity level of at least about 20%, a mass median diameter from 1.

What is claimed is: 1. A composition, for localized delivery to the lungs as a powder, the composition consisting essentially of: particles comprising at least about 95 wt % of amphotericin B, wherein the particles comprise a crystallinity level of at least about 20%, a mass median diameter from 1.1 μm to 1.9 μm, and wherein at least about 80 wt % of the particles have a geometric diameter from 1.1 μm to 1.9 μm. 2. The composition of claim 1, wherein the amphotericin B has a crystallinity level of at least about 70%. 3. The composition of claim 1, wherein the amphotericin B has a crystallinity level of at least about 90%. 4. The composition of claim 1, wherein the amphotericin B has a crystallinity level ranging from about 50% to about 99%. 5. A composition, for localized delivery to the lungs as a powder, the composition consisting essentially of: particles comprising at least about 95 wt % of amphotericin B, the amphotercin B comprising a crystallinity level of at least about 70%, and wherein at least 80 wt % of the particles have a geometric diameter from 1.1 μm to 1.9 μm. 6. The composition of claim 5, wherein the amphotericin B has a crystallinity level of at least about 90%.